AORTECH ENTERS CIRCULATORY SUPPORT MARKET
AORTECH ENTERS CIRCULATORY SUPPORT MARKET ST. PAUL, Minn., June 10 /PRNewswire/ -- AorTech, Inc.
(NASDAQ: AORT) announced today that it has obtained the exclusive worldwide rights to manufacture and distribute two new disposable circulatory support devices developed by the Helmholtz Institute, a leading biomedical research institute in Aachen, Germany. Both products incorporate proprietary design and improved materials, and are novel due to very compact design. These products will enable AorTech to service the circulatory assist markets in intermediate and short-term assist capacities, as well as open a completely new market segment in pediatric applications.
One product, a pneumatically driven, disposable, pulsatile blood pump is computer designed to optimize performance and incorporates proven biocompatible materials and design features to reduce the potential for blood damage during and immediately after open-chest surgery. This paracorporal pump is applied to reversibly damaged natural hearts which need assistance during recovery, short-term post- operative assistance to cardiac function following open chest surgical procedures, or as a bridge to transplant for failing hearts incapable of independent function until a suitable donor heart can be obtained. An additional applications area is ECMO/ECCOR, such as lung failure with hypoxemia massive meconlum aspiration, ARDS (acute respiratory distress syndrome) for neonates, and persistent fetal circulatory syndrome. One unique product feature, the use of unique 3-leaflet plastic-coated valves integrated in the pump, provides significant advantages over existing products utilizing conventionally applied mechanical heart valves. These advantages include less thrombotic events, good washout and no noise or vibration. The second product is a high-efficiency, continuous flow centrifugal blood pump for temporary surgical support use. It is designed for lower priming volume, and a pulsatile mode option. Designed as an alternative to traditional roller pumps, the pump offers advantages with less weight/smaller size, lower blood trauma, reduced anticoagulation regime, lower systemic filling volume, and transportability. Because current economic conditions significantly limit the widespread use of traditional ventricular assist devices, these products' combination of low manufacturing costs, high quality, and performance are expected to result in widespread clinical use in both conventional and non-conventional applications. Greg Ruehle, AorTech's president, stated, "These products offer dramatically enhanced life-saving capabilities and the opportunity to serve exciting new applications. They are the next-generation design of blood pumps, combining new manufacturing and materials technology, disposability, portability, and low cost." -0- 6/10/92 /CONTACT: Gregory J. Ruehle of AorTech, 612-481-1208; or Tom de Petra of de Petra & Associates, 612-338- 7630, for AorTech/ (AORT) CO: AorTech, Inc. ST: Minnesota IN: MTC SU: PDT
KH -- MN008 -- 8872 06/10/92 13:46 EDT
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 10, 1992|
|Previous Article:||MICHAEL KEATON TO IMMORTALIZE HIS HANDPRINTS IN CEMENT AT MANN'S CHINESE THEATER|
|Next Article:||EPA BEGINS REMOVAL ACTIVITIES AT THE MELHORN SILVER RECOVERY SITE IN COALFIELD, TENN.|